Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Maxim Group Downgrades Reed’s to Hold

Maxim Group analyst Anthony Vendetti downgrades Reed's (NASDAQ:REED) from Buy to Hold.
byBenzinga Newsdesk
November 14, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Maxim Group analyst Anthony Vendetti downgrades Reed’s (NASDAQ:REED) from Buy to Hold.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

‘Google’s Privacy Chief Is Out And Will Not Be Replaced; Keith Enright Is Leaving Google After 13 Years As The Tech Giant Restructures Its Privacy And Compliance Teams. Matthew Bye, Director Of Competition Law, Is Also Departing’ – Forbes

By Benzinga Newsdesk
June 4, 12:53 PM
https://www.forbes.com/sites/thomasbrewster/2024/06/04/googles-privacy-chief-is-out-and-will-not-be-replaced/?sh=5f4ae4187fc8Google's chief privacy officer, Keith Enright, will depart the tech giant after 13 years, with

GOOG

Read More

Federal Reserve’s Final 2023 Meeting: FOMC’s Economic Projections Crucial, Dot Plot Weeds Out Hawks, Doves

By Piero Cingari
December 12, 2:52 PM
Fed expected to announce interest rate decision this Wed. Markets expect rates to settle 5.25-5.50%. FOMC will release economic projections, dot plot, & revisiting Sept. projections. Sept. projections showed 2.5% PCE inflation in 2024, 1.5% economic expansion in 2024.

TLT

Read More

iECURE Announces FDA Clearance Of IND Application For ECUR-506 To Initiate OTC-HOPE Trial For Treatment Of Neonatal Onset Ornithine Transcarbamylase Deficiency In The U.S.; NOTE: iECURE Has Licensed The ARCUS Nuclease For ECUR-506 From Precision BioSci…

By Benzinga Newsdesk
April 4, 11:02 AM
Clinical trial sites in the United States, United Kingdom, and Australia will evaluate ECUR-506, an investigational gene editing-based therapy, in newborn males with neonatal onset Ornithine Transcarbamylase (OTC)

DTIL